Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAD603 in Severe to Very Severe Alopecia Areata
NCT07311564Phase 2Recruiting
- Sponsor
- Almirall
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LAD603 in alopecia areata, sponsored by Almirall. Started Dec 2025; status: recruiting.
02
Drugs
LAD603
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT07311564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311564.